secwatch.observer — SEC 8-K summary
======================================

Issuer:     CAPRICOR THERAPEUTICS, INC. (CAPR)
CIK:        0001133869
Form:       8-K
Filed at:   2023-02-16T23:59:59+00:00
Accession:  0001558370-23-001454
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Capricor partners with Nippon Shinyaku for CAP-1002 in Japan; $12M upfront, up to $89M milestones
--------------------------------------------------------------------------------

- Exclusive Japan commercialization and distribution agreement for CAP-1002 in Duchenne muscular dystrophy.
- Capricor receives $12M upfront plus up to ~$89M in development and sales milestones.
- Capricor also gets a meaningful double-digit percentage of product revenue from Japan sales.
- Capricor retains marketing authorization and clinical development; Nippon Shinyaku handles distribution.
- Follows a similar U.S. deal with Nippon Shinyaku signed in January 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133869/000155837023001454/0001558370-23-001454-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133869/000155837023001454/capr-20230210x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-001454

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer